Moderna previews cancer antigen therapy in melanoma ahead of ESMOnews2025-10-13T15:29:30+00:00October 13th, 2025|Endpoints News|
SystImmune’s $250M milestone; Teva’s Uzedy approved to treat bipolar disordernews2025-10-13T14:54:01+00:00October 13th, 2025|Endpoints News|
Tvardi’s stock crashes as STAT3 drug fails Phase 2 after dropouts from side effectsnews2025-10-13T14:15:55+00:00October 13th, 2025|Endpoints News|
Excellergy debuts with $70M Series A and plan to take on Xolairnews2025-10-13T12:00:50+00:00October 13th, 2025|Endpoints News|
Gilead, Arcus’ TIGIT approach exceeds two years of median survival in Phase 2 gastric cancer trialnews2025-10-13T11:19:29+00:00October 13th, 2025|Endpoints News|
Novo Nordisk quits cell therapy as restructure continuesnews2025-10-13T11:05:02+00:00October 13th, 2025|Endpoints News|
Biopharma dealmaking trends: Q3 shows an upticknews2025-10-13T11:00:59+00:00October 13th, 2025|Endpoints News|
Regeneron heads to FDA to seek approval for hearing loss gene therapynews2025-10-13T09:02:48+00:00October 13th, 2025|Endpoints News|
Meet this year’s Women in Biopharma; Peter Marks goes to Eli Lilly; Bob Langer startup launches; and morenews2025-10-11T10:00:36+00:00October 11th, 2025|Endpoints News|
AstraZeneca strikes pricing deal with Trumpnews2025-10-10T22:21:21+00:00October 10th, 2025|Endpoints News|
